Fabio Conforti

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

Fabio Conforti
Feb 23, 2025, 12:04 | Science
Sibylle Loibl: Surrogate End Points for OS in Neoadjuvant Trials for Early Breast Cancer
Sibylle Loibl, Chief Executive Officer of GBG Forschungs GmbH, shared a post on LinkedIn about…
Feb 20, 2025, 07:40 | Science
Francisco J. Esteva: What should be the primary endpoint for FDA registration trials in early-stage breast cancer?
Francisco J. Esteva, Professor of Medicine at the Zucker School of Medicine, shared an article…
Feb 12, 2025, 08:43 | Blog
Carmine Valenza: The evolution of malignant phyllodes tumors of the breast
Carmine Valenza, Medical Oncology Resident at the European Institute of Oncology, shared an article he…
Feb 7, 2025, 14:07 | Science
Hidehito Horinouchi: iDFS reliably predicts final OS in breast cancer
Hidehito Horinouchi, Assistant Chief of the National Cancer Center Hospital, shared a post on X…
Feb 4, 2025, 15:30 | Insight
Breast Cancer Research Digest by Dana-Farber’s Breast Oncology Center
Dana-Farber’s Breast Oncology Center shared a post on X: "Here’s the Breast Cancer Research Digest - a…
Feb 3, 2025, 17:28 | Science
Yakup Ergün: Surrogate End Points for OS in Neoadjuvant RCTs for Early Breast Cancer
Yakup Ergün, Medical Oncologist at Antalya City Hospital, posted on X about recent paper by…
Nov 22, 2024, 17:22 | Insight
Chiara Corti: Estrogen Signaling in Early-Stage Breast Cancer
Chiara Corti, Research Fellow at Dana-Farber Cancer Institute, shared a post on X: “I am…
Nov 2, 2024, 19:57 | Blog
Gregory Riely: Updated NCCN guidelines for treatment of patients with thymoma and thymic carcinoma
Gregory Riely, Medical oncologist at Memorial Sloan Kettering Cancer Center, shared on X: "Updated NCCN…
All: 8 Posts: 1 - 100
Special Coverage